Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 Winter;22(4):361-365.
doi: 10.31486/toj.22.0005.

RAD-140 Drug-Induced Liver Injury

Kenneth Leung  1   2 , Priyanka Yaramada  1   2 , Preeya Goyal  1   3 , Cindy X Cai  1   2   3 , Irene Thung  1   3 , Muhammad B Hammami  1   2   3
Affiliations
Case Reports

RAD-140 Drug-Induced Liver Injury

Kenneth Leung et al. Ochsner J. 2022 Winter.

Abstract

Background: RAD-140, one of the novel selective androgen receptor modulators (SARMs), has potent anabolic effects on bones and muscles with little androgenic effect. Despite the lack of approval for its clinical use, RAD-140 is readily accessible on the consumer market. Hepatotoxicity associated with the use of SARMs has only rarely been reported in the literature. Case Report: A 24-year-old male presented with a 2-week history of diffuse abdominal pain, scleral icterus, pruritus, and jaundice. Prior to presentation, he had been taking the health supplement RAD-140 for muscle growth for 5 weeks. He had a cholestatic pattern of liver injury, with a peak total bilirubin of 38.5 mg/dL. Liver biopsy was supportive of a diagnosis of RAD-140-associated liver injury characterized pathologically by intracytoplasmic and canalicular cholestasis with minimal portal inflammation. Symptoms and liver injury resolved after cessation of the offending agent. Conclusion: To date, only select descriptions of the potential hepatoxicity associated with the use of SARMs, including RAD-140, have been published. Given their potential hepatoxicity and ready availability on the consumer market, RAD-140 and other SARMs should be used judiciously and under close clinical supervision until further hepatic safety data become available.

Keywords: Chemical and drug induced liver injury; Enobosarm; LGD-4033; RAD140.

PubMed Disclaimer

Figures

Figure.
Figure.
(A) Axial contrast-enhanced computed tomography image shows hepatomegaly and focal fatty infiltration (arrow). (B) Magnetic resonance cholangiopancreatography demonstrates patent biliary tree. (C) Liver histology illustrates hepatocellular and canalicular cholestasis (arrows) (hematoxylin and eosin [H&E] stain, magnification ×40). (D) Liver histology reveals minimal portal inflammation (arrow) (H&E stain, magnification ×20).
See this image and copyright information in PMC

References

    1. Solomon ZJ, Mirabal JR, Mazur DJ, Kohn TP, Lipshultz LI, Pastuszak AW. Selective androgen receptor modulators: current knowledge and clinical applications. Sex Med Rev. 2019;7(1):84-94. doi: 10.1016/j.sxmr.2018.09.006 - DOI - PMC - PubMed
    1. Christiansen AR, Lipshultz LI, Hotaling JM, Pastuszak AW. Selective androgen receptor modulators: the future of androgen therapy? Transl Androl Urol. 2020;9(Suppl 2):S135-S148. doi: 10.21037/tau.2019.11.02 - DOI - PMC - PubMed
    1. Basaria S, Collins L, Dillon EL, et al. . The safety, pharmacokinetics, and effects of LGD-4033, a novel nonsteroidal oral, selective androgen receptor modulator, in healthy young men. J Gerontol A Biol Sci Med Sci. 2013;68(1):87-95. doi: 10.1093/gerona/gls078 - DOI - PMC - PubMed
    1. FDA in brief: FDA warns against using SARMs in body building products. U.S. Food and Drug Administration. Published October 31, 2017. Accessed March 8, 2022. fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-bo...
    1. The prohibited list. World Anti-Doping Agency. Published January 1, 2022. Accessed March 8, 2022. wada-ama.org/en/prohibited-list

Publication types

LinkOut - more resources